Loading...

Oncology Venture

OM:OV
Snowflake Description

Overvalued with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OV
OM
SEK206M
Market Cap
  1. Home
  2. SE
  3. Pharmaceuticals & Biotech
Company description

Oncology Venture A/S engages in the research and development of anticancer drugs. The last earnings update was 67 days ago. More info.


Add to Portfolio Compare Print
  • Oncology Venture has significant price volatility in the past 3 months.
OV Share Price and Events
7 Day Returns
-0.5%
OM:OV
1.5%
SE Biotechs
-1.7%
SE Market
1 Year Returns
-
OM:OV
12%
SE Biotechs
-1%
SE Market
OV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oncology Venture (OV) -0.5% -6.8% -36.1% - - -
SE Biotechs 1.5% -1.3% -6.2% 12% 46.5% 77.9%
SE Market -1.7% -5% 0.2% -1% 10% 15%
1 Year Return vs Industry and Market
  • No trading data on OV.
  • No trading data on OV.
Price Volatility
Industry
5yr Volatility vs Market

OV Value

 Is Oncology Venture undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Oncology Venture. This is due to cash flow or dividend data being unavailable. The share price is SEK4.09.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oncology Venture's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oncology Venture's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OM:OV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in DKK DKK-0.44
OM:OV Share Price ** OM (2019-05-24) in SEK SEK4.09
OM:OV Share Price converted to DKK reporting currency Exchange rate (SEK/ DKK) 0.698 DKK2.85
Sweden Biotechs Industry PE Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 27.5x
Sweden Market PE Ratio Median Figure of 323 Publicly-Listed Companies 16.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oncology Venture.

OM:OV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:OV Share Price ÷ EPS (both in DKK)

= 2.85 ÷ -0.44

-6.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncology Venture is loss making, we can't compare its value to the SE Biotechs industry average.
  • Oncology Venture is loss making, we can't compare the value of its earnings to the Sweden market.
Price based on expected Growth
Does Oncology Venture's expected growth come at a high price?
Raw Data
OM:OV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-36.5%per year
Sweden Biotechs Industry PEG Ratio Median Figure of 5 Publicly-Listed Biotechs Companies 2.47x
Sweden Market PEG Ratio Median Figure of 235 Publicly-Listed Companies 1.31x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oncology Venture, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oncology Venture's assets?
Raw Data
OM:OV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in DKK DKK3.08
OM:OV Share Price * OM (2019-05-24) in SEK SEK4.09
OM:OV Share Price converted to DKK reporting currency Exchange rate (SEK/ DKK) 0.698 DKK2.85
Sweden Biotechs Industry PB Ratio Median Figure of 41 Publicly-Listed Biotechs Companies 3.76x
Sweden Market PB Ratio Median Figure of 568 Publicly-Listed Companies 2.47x
OM:OV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:OV Share Price ÷ Book Value per Share (both in DKK)

= 2.85 ÷ 3.08

0.93x

* Primary Listing of Oncology Venture.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncology Venture is good value based on assets compared to the SE Biotechs industry average.
X
Value checks
We assess Oncology Venture's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oncology Venture has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OV Future Performance

 How is Oncology Venture expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-36.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oncology Venture expected to grow at an attractive rate?
  • Unable to compare Oncology Venture's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Oncology Venture's earnings growth to the Sweden market average as it is expected to be loss making during the next 1-3 years.
  • Oncology Venture's revenues are expected to decrease over the next 1-3 years, this is below the Sweden market average.
Annual Growth Rates Comparison
Raw Data
OM:OV Future Growth Rates Data Sources
Data Point Source Value (per year)
OM:OV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -36.5%
OM:OV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -52.4%
Sweden Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.4%
Sweden Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 19.9%
Sweden Market Earnings Growth Rate Market Cap Weighted Average 8.7%
Sweden Market Revenue Growth Rate Market Cap Weighted Average 4.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OM:OV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in DKK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OM:OV Future Estimates Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 4 -91 1
2019-12-31 4 -204 1
OM:OV Past Financials Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income *
2018-12-31 10 -28 -15
2018-09-30 3 -42 -14
2018-03-31 2 -32 -43
2017-12-31 9 -8 -30
2017-09-30 7 -19 -38
2017-06-30 6 -19 -38
2017-03-31 0 -36 -31
2016-12-31 1 -28 -26
2016-09-30 4 -30 -18
2016-06-30 4 -24 -14
2016-03-31 4 -18 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oncology Venture is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Oncology Venture's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OM:OV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Oncology Venture Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:OV Future Estimates Data
Date (Data in DKK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -1.63 -1.63 -1.63 1.00
2019-12-31 -3.87 -3.87 -3.87 1.00
OM:OV Past Financials Data
Date (Data in DKK Millions) EPS *
2018-12-31 -0.44
2018-09-30 -0.97
2018-03-31 -3.71
2017-12-31 -1.27
2017-09-30 -1.84
2017-06-30 -2.19
2017-03-31 -2.91
2016-12-31 -2.58
2016-09-30 -1.94
2016-06-30 -1.52
2016-03-31 -1.51

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Oncology Venture will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Oncology Venture's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Sweden market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Sweden market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oncology Venture has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OV Past Performance

  How has Oncology Venture performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oncology Venture's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oncology Venture does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Oncology Venture's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oncology Venture's 1-year growth to the SE Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oncology Venture's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oncology Venture Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:OV Past Revenue, Cash Flow and Net Income Data
Date (Data in DKK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 9.52 -14.94 9.10
2018-09-30 3.41 -14.07 -7.76
2018-03-31 1.73 -43.18 3.78
2017-12-31 9.05 -30.39 19.07
2017-09-30 6.68 -38.40 18.04
2017-06-30 5.76 -37.55 17.11
2017-03-31 -0.13 -31.38 1.93
2016-12-31 1.01 -26.03 1.92
2016-09-30 4.07 -18.03 1.72
2016-06-30 3.59 -14.12 -0.14
2016-03-31 3.66 -10.95 -0.15
2015-12-31 2.49 -7.88 0.61
2014-12-31 0.06 -0.42
2013-12-31 -0.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oncology Venture has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Oncology Venture has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oncology Venture improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oncology Venture's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oncology Venture has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OV Health

 How is Oncology Venture's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oncology Venture's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oncology Venture's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Oncology Venture's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Oncology Venture's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oncology Venture Company Filings, last reported 4 months ago.

OM:OV Past Debt and Equity Data
Date (Data in DKK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 181.86 18.89 1.55
2018-09-30 172.80 9.30 8.74
2018-03-31 53.83 0.00 29.11
2017-12-31 2.45 0.00 3.33
2017-09-30 66.35 0.00 14.71
2017-06-30 76.06 0.00 28.99
2017-03-31 45.20 0.00 15.19
2016-12-31 36.75 0.00 14.64
2016-09-30 31.27 0.00 9.11
2016-06-30 38.37 0.00 16.46
2016-03-31 28.01 0.00 8.81
2015-12-31 33.89 0.00 13.66
2014-12-31 0.49 0.03 0.01
2013-12-31 0.91 0.03 0.27
  • Oncology Venture's level of debt (10.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (3.3% vs 10.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oncology Venture has less than a year of cash runway based on current free cash flow.
  • Oncology Venture has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.8% each year.
X
Financial health checks
We assess Oncology Venture's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oncology Venture has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OV Dividends

 What is Oncology Venture's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oncology Venture dividends. Estimated to be 0% next year.
If you bought SEK2,000 of Oncology Venture shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oncology Venture's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oncology Venture's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OM:OV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Sweden Market Average Dividend Yield Market Cap Weighted Average of 244 Stocks 3.3%
Sweden Minimum Threshold Dividend Yield 10th Percentile 1.2%
Sweden Bottom 25% Dividend Yield 25th Percentile 1.8%
Sweden Top 25% Dividend Yield 75th Percentile 4.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OM:OV Future Dividends Estimate Data
Date (Data in DKK) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oncology Venture has not reported any payouts.
  • Unable to verify if Oncology Venture's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oncology Venture's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oncology Venture has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Oncology Venture's dividends in 3 years as they are not expected to pay a notable one for Sweden.
X
Income/ dividend checks
We assess Oncology Venture's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oncology Venture afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oncology Venture has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OV Management

 What is the CEO of Oncology Venture's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Jensen
COMPENSATION DKK1,166,000
AGE 63
TENURE AS CEO 7.3 years
CEO Bio

Mr. Peter Buhl Jensen, Adj Professor, MD, PhD serves as Chief Executive Officer and Member of Executive Board at Medical Prognosis Institute A/S. Mr. Jensen is the Founder of Oncology Venture A/S and has been its Chief Executive Officer since 2012. He serves as a Director at Oncology Venture A/S since 2012. He has been the Chief Executive Officer of Oncology Venture ApS since 2012. Mr. Jensen serves as the Chief Executive Officer of TopoTarget UK Limited. He serves as Clinical Scientific Advisor of WntResearch AB. He co-founded TopoTarget A/S in 2000 and served as its Chief Executive Officer until February 23, 2010. He ensured development, approval and launch of the oncology product Totect/Savene in USA and in Europe. He led the establishment of sales forces in both market regions. He served as the Chief of The Laboratory of Experimental Medical Oncology and is a Consultant Medical Oncologist at The National University Hospital, Copenhagen. He is a successful entrepreneur innovating within the drug development field. He was a Senior Consultant at the Department of Oncology at Aalborg Hospital. Mr. Jensen has 15 years of management experience in cancer research and translational drug development. He has significant management experience in cancer research and translational drug development. He is a specialist in internal medicine. He served as the Chairman of WntResearch AB since 2010 and also serves its Director. He served as the Chairman of LiPlasome Pharma ApS. He serves as Director of LiPlasome Pharma ApS, Vecata Invest A/S, AntiAnthra ApS, LiPlasome A/S and Symbion Fonden. He serves as a Director of Medical Prognosis Institute A/S and of Mirrx A/S. He serves as a Director of Vecata A/S and Proof of Concept Board- DTU-KU-Risø. He served as a Director of Affibody Medical AB (publ) since July 4, 2007. He served as a Director of PledPharma AB since 2011. He served as a Director of TopoTarget A/S from 2000 to June 2, 2009. He served as a Director of Aprea AB and Axelar AB. He has published more than 80 papers on cancer and its treatment. He serves as Honorary Professor of Clinical Oncology at Københavns Universitet. Mr. Jensen studied MD from the University of Copenhagen and Gold Medal, Specialist in internal medicine, PhD in preclinical cancer therapeutics evaluation.

CEO Compensation
  • Peter's compensation has increased whilst company is loss making.
  • Peter's remuneration is lower than average for companies of similar size in Sweden.
Management Team Tenure

Average tenure and age of the Oncology Venture management team in years:

4.3
Average Tenure
59
Average Age
  • The tenure for the Oncology Venture management team is about average.
Management Team

Peter Jensen

TITLE
Founder
COMPENSATION
DKK1M
AGE
63
TENURE
7.3 yrs

Steen Knudsen

TITLE
Founder
AGE
57

Ulla Buhl

TITLE
Founder
AGE
54

Dan Von Hoff

TITLE
AGE
70

Claus Pedersen

TITLE
Chief Commercial Officer
AGE
46
TENURE
1.3 yrs

Niels Laursen

TITLE
Chief Financial Officer
AGE
62
TENURE
5.3 yrs

Thomas Jensen

TITLE
Chief Technology Officer
AGE
40
TENURE
3.3 yrs

Annie Rasmussen

TITLE
Chief of Clinical Operations
AGE
61
Board of Directors Tenure

Average tenure and age of the Oncology Venture board of directors in years:

4.8
Average Tenure
59
Average Age
  • The tenure for the Oncology Venture board of directors is about average.
Board of Directors

Duncan Moore

TITLE
Chairman
COMPENSATION
DKK127K
AGE
59
TENURE
4.3 yrs

Peter Jensen

TITLE
Founder
COMPENSATION
DKK1M
AGE
63
TENURE
7.3 yrs

Frank Knudsen

TITLE
Vice Chairman
AGE
60

Steen Knudsen

TITLE
Founder
AGE
57
TENURE
15.3 yrs

Ulla Buhl

TITLE
Founder
AGE
54
TENURE
4.3 yrs

Carani Sanjeevi

TITLE
Director
COMPENSATION
DKK64K
AGE
60
TENURE
4.3 yrs

Magnus Persson

TITLE
Director
AGE
58
TENURE
5.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
X
Management checks
We assess Oncology Venture's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oncology Venture has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OV News

Simply Wall St News

OV Company Info

Description

Oncology Venture A/S engages in the research and development of anticancer drugs. Its product pipeline includes LiPlaCis, a liposomal formulation of cisplatin, which is in Phase II clinical trials for the treatment of breast and prostate cancer; 2X-121, a PARP inhibitor in Phase II clinical trials for the treatment of breast cancer; Dovitinib, a multi-tyrosine kinase inhibitor; 2X-111, a liposomal formulation of doxorubicin in Phase II clinical trials for the treatment of breast cancer; and APO010, an immuno-oncology product in Phase I/II clinical trials for the treatment multiple myeloma. The company has a strategic collaboration with the German Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie and the Danish Breast Cancer Corporative Group to develop precision medicine for women's cancers. Oncology Venture A/S was founded in 2012 and is headquartered in Hørsholm, Denmark.

Details
Name: Oncology Venture A/S
OV
Exchange: OM
Founded: 2012
SEK205,773,127
50,311,278
Website: http://www.oncologyventure.com
Address: Oncology Venture A/S
Venlighedsvej 1,
Hørsholm,
Capital Region of Denmark, 2970,
Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM OV Ordinary Shares OMX Nordic Exchange Stockholm SE SEK 25. Aug 2018
Number of employees
Current staff
Staff numbers
12
Oncology Venture employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/26 22:38
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/03/20
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.